Amlexanox Evidence Guide
Amlexanox has a small Phase 2 human pilot showing metabolic improvement in a subset of obese insulin-resistant patients, but the trial was underpowered and the responder phenotype is not well-characterized. The IKKe/TBK1 mechanism is scientifically interesting as a non-GLP-1 weight-loss target. At this stage, amlexanox is more useful for mechanistic research into inflammatory obesity than as a standalone weight-loss protocol.
Our Take
Amlexanox has a small Phase 2 human pilot showing metabolic improvement in a subset of obese insulin-resistant patients, but the trial was underpowered and the responder phenotype is not well-characterized. The IKKe/TBK1 mechanism is scientifically interesting as a non-GLP-1 weight-loss target. At this stage, amlexanox is more useful for mechanistic research into inflammatory obesity than as a standalone weight-loss protocol.
- Best for
- IKKe/TBK1 pathway research, inflammatory obesity mechanistic studies, insulin resistance investigation
- Evidence grade
- Level C
- Confidence
- Moderate
- Starting point
- 75mg oral daily (dose used in Phase 2 pilot)
Benefits and Evidence
- Insulin Sensitivity: Level C, includes human evidence - Modest improvements in insulin sensitivity and glycemic control observed in Phase 2 trials in patients with type 2 diabetes and obesity, though results were variable between studies.
- Weight Loss: Level C, includes human evidence - Small but significant reductions in body weight observed in some trial participants, with greater effects in patients with higher baseline IKKε expression in adipose tissue.
- Hepatic Steatosis Reduction: Level D, mostly non-human evidence - Reduction in liver fat content demonstrated in animal models of NAFLD through promotion of hepatic fatty acid oxidation.
Side Effects and Warnings
- Diarrhea
- Nausea
- Upper respiratory tract infection
- Headache
- Contact dermatitis (topical use)
- Oral use for metabolic indications is investigational - not FDA approved for this purpose
- FDA-approved only as a topical treatment for canker sores
- Phase 2 trials showed variable efficacy, with some failing to meet primary endpoints
Research Dosage References
- <strong>Oral</strong> - 100 mg - Three times daily - Dosage used in Phase 2 metabolic trials. Higher doses were associated with more GI side effects.
- <strong>Topical (approved use)</strong> - 5% paste - 4 times daily - FDA-approved dosage for aphthous ulcers only. Applied directly to the ulcer.
Mechanism of Action
Amlexanox inhibits IKKε and TBK1, two kinases that are upregulated in obesity and contribute to the development of insulin resistance through promotion of chronic low-grade inflammation. IKKε and TBK1 act as a counterregulatory brake on energy expenditure - their activation in obese adipose tissue reduces thermogenesis and promotes energy storage. By inhibiting IKKε and TBK1, amlexanox reverses catecholamine resistance in adipose tissue, restoring the thermogenic response to beta-adrenergic signaling. This leads to increased energy expenditure through activation of UCP1-mediated uncoupling in brown and beige adipocytes. Additionally, amlexanox reduces hepatic steatosis by promoting fatty acid oxidation in the liver and improves insulin sensitivity through reduction of inflammatory signaling in adipose tissue. The anti-inflammatory effects extend beyond the NF-κB pathway to include modulation of inflammasome activity and reduction of pro-inflammatory cytokine production.
Legal Status
FDA approved as a topical agent (Aphthasol) for aphthous ulcers. Systemic use for metabolic indications is investigational.
Primary Sources
- Amlexanox, an inhibitor of IKKε and TBK1, reverses obesity and metabolic dysfunction in mice. Nature Medicine, 2013.
- A randomized trial of amlexanox in the treatment of obesity and type 2 diabetes. Cell Metabolism, 2017.